RT Journal Article SR Electronic(1) A1 Yam, Karen K. A1 Hugentobler, Felix A1 Pouliot, Philippe A1 Stern, Andrew M. A1 Lalande, Jean-Daniel A1 Matlashewski, Greg A1 Olivier, Martin A1 Cousineau, BenoitYR 2011 T1 Generation and evaluation of A2-expressing Lactococcus lactis live vaccines against Leishmania donovani in BALB/c mice JF Journal of Medical Microbiology, VO 60 IS 9 SP 1248 OP 1260 DO https://doi.org/10.1099/jmm.0.029959-0 PB Microbiology Society, SN 1473-5644, AB Leishmaniasis is a parasitic disease affecting over 12 million individuals worldwide. As current treatments are insufficient, the development of an effective vaccine is a priority. This study generated and assessed the efficacy of Leishmania vaccines engineered from the non-colonizing, non-pathogenic Gram-positive bacterium Lactococcus lactis. A truncated, codon-optimized version of the A2 antigen from Leishmania donovani was engineered for expression in Lactococcus lactis in three different subcellular compartments: in the cytoplasm, secreted outside the cell or anchored to the cell wall. These three A2-expressing Lactococcus lactis strains were tested for their ability to generate A2-specific immune responses and as live vaccines against visceral Leishmania donovani infection in BALB/c mice. Subcutaneous immunization with live Lactococcus lactis expressing A2 anchored to the cell wall effectively induced high levels of antigen-specific serum antibodies. It was demonstrated that Lactococcus lactis-based vaccines are a feasible approach in the generation of live vaccines against leishmaniasis. The Lactococcus lactis strains generated in this study provide an excellent foundation for further studies on live bacterial vaccines against leishmaniasis and other pathogens., UL https://www.microbiologyresearch.org/content/journal/jmm/10.1099/jmm.0.029959-0